Startup Dossier
Cyberna
Cyberna is developing ultra-early cancer detection tests based on epitranscriptomic biomarkers, combining RNA chemistry, mass spectrometry, and machine learning to identify cancer before tumors become clinically detectable. Spin-off from LIRMM (CNRS) and IRCM (INSERM), with the ecosystem of CHU de Montpellier, University of Montpellier, and SATT AxLR.
Total Raised
€860.0B
About
Cyberna is developing ultra-early cancer detection tests based on epitranscriptomic biomarkers, combining RNA chemistry, mass spectrometry, and machine learning to identify cancer before tumors become clinically detectable. Spin-off from LIRMM (CNRS) and IRCM (INSERM), with the ecosystem of CHU de Montpellier, University of Montpellier, and SATT AxLR.
Structural DNA
Legal Name
Cyberna
Legal Form
SAS
SIREN
982558124